Europe
It was a busy week for clinical trial announcements. Take a look.
A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The announcement for the chikungunya vaccine (VLA1553) comes after the U.S. FDA awarded it with a Breakthrough Designation status. Read more about it here.
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
With the acquisition of the Roche stake, SoftBank has become one of the company’s biggest stakeholders.
The FDA-initiated partial hold on Novartis’ gene therapy trial for spinal muscular atrophy has been lifted recently. Here’s everything you need to know about it.
BeiGene is building a new research and development and manufacturing facility on a 42-acre campus in New Jersey, while MorphoSys is now growing its presence in the greater Boston area.
Late-phase trial data show Servier’s TIBSOVO, in conjunction with chemotherapy azacitidine, prolonged event-free survival in adult patients with previously untreated IDH1-mutated acute myeloid leukemia.
The financing will be used to advance the company’s IMVT-1401 candidate across several different autoimmune disorder indications.
PRESS RELEASES